Management of diabesity: Current concepts

Table 1 The benefits of different glucagon-like peptide-1 agonist molecules in the management of diabesity based on recent landmark clinical trials[103]

Drug molecule	Mean weight reduction in kg (95%CI)	Mean % HbA1c reduction (95%CI)	Follow-up period (yr)
Exenatide (weekly)	-1.27 (-1.4 to -1.13)	-0.53 (-0.57 to -0.50)	3.2
Liraglutide	-2.3 (-2.5 to -2.0)	-0.40 (-0.45 to -0.34)	3.8
Lixisenatide	-0.7 (-0.9 to -0.5)	-0.27 (-0.31 to -0.22)	2.1
Albiglutide	-0.83 (-1.06 to -0.60)	-0.52 (-0.58 to -0.45)	1.5
Dulaglutide	-1.46 (-1.67 to -1.25)	-0.61 (-0.65 to -0.58)	5.4
Semaglutide	-2.87 (-3.47 to –2.28) for 0.5 mg	-0.66 (-0.80 to – 0.52) for 0.5 mg	2.0
	-4.5 (-4.94 to -3.75) for 1 mg	-1.05 (-1.19 to -0.91) for 1 mg

HbA1C: Haemoglobin; CI: Confidence interval.

Table 2 The beneficial effects of different sodium glucose cotransporter-2 inhibitors in the management of diabesity based on recent landmark clinical trials[104-108]

Ref.	Drug molecule	Mean weight reduction in kg (SE/95%CI)	Mean % haemoglobin reduction (95%CI)	Follow-up
Neal et al[104], 2017 (CANVAS)	Canagliflozin	-1.60 (- 1.70 to -1.51)	-0.58 (-0.61 to -0.56)	3.5 yr
Wiviott et al[105], 2019 (DECLARE)	Dapagliflozin	-1.80 (-2.00 to -1.70)	-0.42 (-0.45 to -0.40)	4.2 yr
Häring et al[106], 2014 (EMPA-REG)	Empagliflozin	-1.63 (-2.11 to -1.5) for 10 mg	-0.57 (-0.70 to -0.43) for 10 mg	24 wk
		-2.01 (-2.49 to -1.53) for 25 mg	-0.64 (-0.77 to -0.50) for 25 mg
Rosenstock et al[107], 2018 (VERTIS-MET)	Ertugliflozin	-3.00 (-3.30 to -2.70) for 5 mg	-0.70 (-0.90 to -0.50) for 5 mg	24 wk
		-2.90 (-3.20 to -2.60) for 15 mg	-0.90 (-1.00 to -0.70) for 15 mg
Dagogo-Jack et al[108], 2018 (VERTIS-SITA)	Ertugliflozin	-2.0 (-2.7 to -1.4) for 5 mg	-0.70 (-0.90 to -0.50) for 5 mg	26 wk
		-1.7 (-2.4 to -1.1) for 10 mg	-0.80 (-0.90 to -0.60) for 10 mg

HbA1C: Haemoglobin; CI: Confidence interval.